Kakogawa, Japan

Keiji Kameyama

This inventor holds 8 USPTO granted patents, plus 2 CIPO patents. Top assignee: Kanegafuchi Kagaku Kogyo Kabushiki Kaisha. Active years: 1989-1994.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keiji Kameyama. Retrieved from https://idiyas.com/inventor/keiji-kameyama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 8.1

ph-index = 5

Forward Citations = 119(Granted Patents)


Location History:

  • Kakogawa, JP (1989 - 1993)
  • Mihara, JP (1994)

Company Filing History:


Years Active: 1989-1994

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Keiji Kameyama: Innovator in Antihyperlipidemic Compounds

Introduction

Keiji Kameyama, based in Kakogawa, Japan, is a prominent inventor recognized for his contributions to pharmaceutical innovations. With a total of 8 patents to his name, Kameyama is making strides in the development of antihyperlipidemic compositions, which play a critical role in managing lipid levels in patients.

Latest Patents

Among his latest patents are the developments of cinnamamide derivatives. These derivatives encompass both the compound itself and its pharmaceutically acceptable salts. The compositions Kameyama has been working on include an active ingredient that consists of either the cinnamamide derivative or its salts. The advancements present new possibilities in treating hyperlipidemia, a condition that can lead to more severe health issues if left untreated.

Career Highlights

Kameyama is currently employed at Kanegafuchi Kagaku Kogyo Kabushiki Kaisha, where he focuses on research and development in the field of pharmaceuticals. His innovative spirit and dedication have led him to become a key figure in the invention of antihyperlipidemic agents, contributing to better health outcomes for many.

Collaborations

Throughout his career, Kameyama has collaborated with notable colleagues, including Ikuo Katsumi and Tadayoshi Shiraishi. Their joint efforts in the lab have fostered a collaborative environment conducive to scientific breakthroughs, enabling the creation of effective treatments.

Conclusion

Keiji Kameyama exemplifies the spirit of innovation in the pharmaceutical industry, providing solutions that address significant health challenges. As he continues to develop new compounds and compositions, his work will undoubtedly impact medical science and patient care positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…